Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudwaleit

Showing results (81-90 of 136) with videos related to

Pageof 14
Sort By:
Rheumatology (Oxford, England)|November 25, 2004
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitisJ Brandt, J Listing, H Haibel, et al.
Annals of the Rheumatic Diseases|July 10, 2007
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled studyJ Sieper, T Klopsch, M Richter, et al.
Arthritis and Rheumatism|December 13, 2005
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging dataX Baraliakos, J Brandt, J Listing, et al.
Annals of the Rheumatic Diseases|August 12, 2006
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trialH Haibel, H C Brandt, I H Song, et al.
Zeitschrift Fur Rheumatologie|November 23, 2006
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]J Braun, J Zochling, E Märker-Hermann, et al.
Genes and Immunity|February 24, 2001
Interethnic studies of TNF polymorphisms confirm the likely presence of a second MHC susceptibility locus in ankylosing spondylitisA Milicic, F Lindheimer, S Laval, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2000
Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR allelesA K Mertz, P Wu, T Sturniolo, et al.
Annals of the Rheumatic Diseases|June 20, 2007
Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondyloarthritisC E Althoff, H Appel, M Rudwaleit, et al.
Arthritis Care & Research|October 4, 2016
Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic ArthritisD van der Heijde, A Deodhar, R Fleischmann, et al.
Arthritis and Rheumatism|June 10, 2003
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitisJ Brandt, A Khariouzov, J Listing, et al.
Pageof 14

Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
Rheumatology (Oxford, England)|November 25, 2004
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitisJ Brandt, J Listing, H Haibel, et al.
Annals of the Rheumatic Diseases|July 10, 2007
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled studyJ Sieper, T Klopsch, M Richter, et al.
Arthritis and Rheumatism|December 13, 2005
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging dataX Baraliakos, J Brandt, J Listing, et al.
Annals of the Rheumatic Diseases|August 12, 2006
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trialH Haibel, H C Brandt, I H Song, et al.
Zeitschrift Fur Rheumatologie|November 23, 2006
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]J Braun, J Zochling, E Märker-Hermann, et al.
Genes and Immunity|February 24, 2001
Interethnic studies of TNF polymorphisms confirm the likely presence of a second MHC susceptibility locus in ankylosing spondylitisA Milicic, F Lindheimer, S Laval, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2000
Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR allelesA K Mertz, P Wu, T Sturniolo, et al.
Annals of the Rheumatic Diseases|June 20, 2007
Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondyloarthritisC E Althoff, H Appel, M Rudwaleit, et al.
Arthritis Care & Research|October 4, 2016
Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic ArthritisD van der Heijde, A Deodhar, R Fleischmann, et al.
Arthritis and Rheumatism|June 10, 2003
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitisJ Brandt, A Khariouzov, J Listing, et al.
Pageof 14